Skip to main content
Fast-track status granted to Imara's sickle cell disease drug

Imara announced that the FDA has granted fast-track status to its experimental drug IMR-687, being developed to diminish sickling of red blood cells in patients with sickle cell disease. The investigational treatment is being evaluated in a Phase IIa trial with 54 patients who have sickle cell anemia.

Full Story: